Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Active not recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Lymphoma, Large B-Cell, Diffuse 12Burkitt Lymphoma 10Neoplasms 7Lymphoma, Follicular 7Sarcoma 6Triple Negative Breast Neoplasms 5Ovarian Neoplasms 5Lymphoma 5Endometrial Neoplasms 5Breast Neoplasms 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Liposarcoma 4Hodgkin Disease 4Sarcoma, Ewing 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Osteosarcoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Biphenotypic, Acute 3Leiomyosarcoma 3Histiocytoma, Malignant Fibrous 3Fallopian Tube Neoplasms 3Dermatofibrosarcoma 3Sarcoma, Synovial 2Sarcoma, Clear Cell 2Neurofibrosarcoma 2Neuroblastoma 2

Interventions

Cyclophosphamide 10Nivolumab 7pembrolizumab 6fludarabine phosphate 6fludarabine 5Mycophenolic Acid 5Specimen Handling 4Magnetic Resonance Spectroscopy 4Doxorubicin 4Dacarbazine 4Cyclosporine 4Brentuximab Vedotin 4Whole-Body Irradiation 3Vinblastine 3Radiotherapy 3Filgrastim 3Etoposide 3Busulfan 3Tacrolimus 2Sirolimus 2Radiation 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Clofarabine 2Carmustine 2tocilizumab 1thymoglobulin 1tafasitamab 1polatuzumab vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Hodgkin Disease × Doxorubicin × 30 days × Clear all
NCT01476410 2026-05-22

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Northwestern University

Phase 2 Completed
49 enrolled 25 charts
Lymphoid

Hodgkin Disease

NCT07551583 2026-05-20

Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
15 enrolled
Lymphoid

Hodgkin Disease

NCT01920932 2026-05-06

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
77 enrolled 20 charts
Lymphoid

Hodgkin Disease, Neoplasms

NCT03907488 2026-05-04

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
994 enrolled 11 charts 1 FDA
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡